In the past I've been critical of the Arizona Republic for burying bioscience news in the Business section. Well... On 8 August 02010, the Republic had bioscience on page A1 and for that I say Thank You.

Bioscience news is consistently good news and should be A1 news.

AzCentral.com::Trailblazer drives new ways of cancer care

P.S. I sure am glad Dr. Daniel Von Hoff is an Arizonan.

My AzCentral.com blog posting -- Keep bioscience news on A1 -- generated zero comments.

[29 August 2010, top]

   "California is poised to lead not only this country, but all 
    countries on stem cell research. We cannot fall behind the 
    nations who are making this life-saving science a priority"
    -- Arnold Schwarzenegger, California Governer

[29 August 2010, top]

   "Arguably, you will find no other greater concentration of 
    biotechnology than in Northern California, the birthplace 
    of biotechnology. We stand arm-in-arm with San Diego and 
    Boston/Cambridge."

Xconomy.com::How Bay Area Biotech Stacks Up With the Rest of the World

[23 August 2010, top]

   "Over the next 20 years, synthetic genomics is going to become 
    the standard for making anything." -- Venter in 2007

SPIEGEL interviewed Craig Venter in 2010.

   "SPIEGEL: So the Human Genome Project has had very 
             little medical benefits so far?"

   "Venter: Close to zero to put it precisely."

SPIEGEL.de::Interview with Craig Venter

[21 August 2010, top]

   "[...] give patients the same medicinal benefits as marijuana 
    without its mind-altering properties."

If somebody is grossly ill, then should get pain relief with the option of taking a "trip."

Futurity.org::Pain relief (sans trip) via body's 'marijuana'

[17 August 2010, top]

   "When we look back in 25 years, putting the first embryonic 
    stem cells into humans will prove as momentous as man's 
    first step on the moon." -- Chris Mason, professor of 
    regenerative medicine at University College London

Only time will tell of professor Mason is right or wrong.

NewScientist.com::Green light for first embryonic stem cell treatment

[03 August 2010, top]

   "Recent improvements in sequencing technology ('next-gen' 
    sequencing platforms) have sharply reduced the cost of 
    sequencing. The 1000 Genomes Project is the first project 
    to sequence the genomes of a large number of people, to 
    provide a comprehensive resource on human genetic variation."

We are living in the Age of Genomics.

BCM is the Baylor College of Medicine.

BCM.edu::1000 Genomes project releases pilot data

[08 July 2010, top]

   "Arteriocyte, a clinical stage Biotechnology company with 
    offices in Cleveland, Ohio and Hopkinton, Massachusetts, 
    is developing proprietary stem cell and tissue engineering 
    based therapies."

DARPA knows about Arteriocyte.

   "We're basically mimicking bone marrow in a lab environment," 
    company CEO Don Brown tells Danger Room. "Our model works, but 
    we need to extrapolate our production abilities to make scale."

Wired.com::DARPA's Genetically Engineered Blood Starts Pumping

[08 July 2010, top]

CloserLookAtStemCells.orgs::Considering stem cell treatment?

[02 July 2010, top]

   "It's a new technology that uses molecular therapy to coax adult 
    cells to revert to an embryonic stem cell-like state, allowing 
    scientists to later re-differentiate these cells into specific 
    types with the potential to treat heart attacks or diseases such 
    as Parkinson's. But at this point in the technology's development, 
    only one percent of cells are successfully being reprogrammed."

Kudos to Tel Aviv University and Harvard University.

LabSpaces.net::Turning back the cellular clock

[29 June 2010, top]

[09 June 2010, top]

First, Ann Arbor-based Aastrom Biosciences announced it has formed a scientific advisory board in order to gain "guidance and expertise in stem cell biology and cardiovascular disease."

Second, an interview with Aastrom's CEO has been posted to the web.

   "The biggest challenge for Aastrom is that a lot of people 
    in the life sciences industry think stem cell therapies 
    are many years away from being commercialized. At Aastrom, 
    we don't think we're that far away." -- Tim Mayleben, CEO

MedCityNews.com::Q&A: Aastrom Biosciences' CEO Tim Mayleben

[14 April 2010, top]

• TGen plays a role in a new study by the National Institute
  on Aging about a gene linked to Alzheimer's disease: 
  http://is.gd/bpNCs [2010.04.12]
  

• TGen's Dr. Eric Reiman is one of several neuroscientists 
  and clinicians discussing memory loss at a Florida conference:
  http://is.gd/bfHk9 [2010.04.05]
  

• TGen is using an Isilon IQ network-attached storage system, 
  capable of scaling up to 10.4 petabytes of capacity: 
  http://is.gd/bfHgO [2010.04.05]
  

• Construction will start soon on the $187 million, 
  268,000-square-foot Health Sciences Education Building 
  next to TGen: http://is.gd/aUVvi [2010.03.23]
  

[12 April 2010, top]

[10 April 2010, top]

   Fact of the Day: W/O #hcr by 2019, employment-based spending 
   on health care at large employers will be 166% higher

My burning question: How are politicians factoring in advances in HPC-based 21st century Informatics, biotechnology, molecular nanotechnology, and robotics?

I know the answer: They aren't!

If the tweet was a "fact of the day," then that is political bullfoo the nth-degree.

[03 March 2010, top]

   "A team of Howard Hughes Medical Institute (HHMI) researchers 
    has found that in old mice, a several-week exposure to the 
    blood of young mice causes their bone marrow stem cells to 
    act 'young' again."

HHMI.org::Making Old Stem Cells Act Young Again

[01 February 2010, top]

   "We are a data company." Cliff Reid, CEO Complete Genomics

SingularityHub.com::Exclusive: Complete Genomics To Sequence 1 Million Genomes -- Interview With CEO

Just like Google, Complete Genomics, Inc. is located in Mountain View, California.

Complete Genomics scientific advisory board on 27 January 2010.

   Dr. Mark Chee, CEO/CSO of Prognosys Biosciences, Inc. 
   Dr. George Church, Professor of Genetics at Harvard Medical 
       School and Director of the Center for Computational Genetics
   Dr. Leroy Hood, President of the Institute for Systems Biology
   Dr. Douglas A. Lauffenburger, Uncas & Helen Whitaker Professor 
       of Bioengineering and Director of the Biological Engineering 
       Division at MIT, and also holds appointments in the Department 
       of Biology and the Department of Chemical Engineering

CompleteGenomics.com::Powering large-scale human genome studies

[27 January 2010, top]

WashingtonPost.com::Using genetic information to match singles with potential partners

[24 January 2010, top]

	National Geographic: "Merging Man And Machine - A Better 
	Life With Bionics" http://bit.ly/8sWl22

[23 January 2010, top]

   Beyond Legos: Berkeley Lab helps launch first open-source 
   genetic parts production facility http://bit.ly/5zJxmI

Berkeley.edu reported that they are establishing BIOFAB.

   "International Open Facility Advancing Biotechnology (BIOFAB), 
    aims to produce thousands of free, standardized DNA parts to 
    shorten the development time and lower the cost of synthetic 
    biology for academic or biotech laboratories."

Berkeley.edu::NSF grant to launch world's first open-source genetic parts production facility

[21 January 2010, top]

My initial response was: "I'm assuming it would; therefore, I hope so." But... the keyword in my reponse is "hope." In other words, I haven't a clue.

   "The key is to shift from diagnosing patients when they already 
    have symptoms to detecting disease much earlier, before symptoms 
    appear. This is the potential that molecular medicine brings to 
    personalized healthcare delivery. Personalized healthcare will 
    be predictive and preventive, probing an individual's unique 
    biology to assess disease probability and then designing 
    appropriate treatments, even before symptoms."
    --Matthew O'Donnell, Dean of the University of 
      Washington's College of Engineering 

I'm still clueless after reading O'Donnell's article at Xconomy.com, but I'm still hoping that molecular medicine will make significant advances over the span of the next decade.

Xconomy.com::Can Molecular Medicine Survive Its Teenage Years, and Reach its Potential This Decade?

[15 January 2010, top]

   Illumina (nasdaq: ILMN) HiSeq 2000 can sequence a human 
   genome for less than $10K. (pr) http://ow.ly/VZd9

We're living in the Genomics Age and the cost of genome sequencing keeps getting cheaper and cheaper.

[13 January 2010, top]

   "induced pluripotent stem cells" #IPScells 
   ScientificAmerican.com http://ow.ly/S0lK

[03 January 2010, top]

Biotech Trekker Archives: 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003-02

[01 January 2010, top]